Company intelligence / Profile preview

Epinex Diagnostics

Tustin, California, United States

Ownership: Private
Employees: ~25
Development stage: Other

Overview

Epinex Diagnostics has developed and prototyped the G1A™ Rapid Diabetes Monitoring Index Test for measuring glycated albumin, aiming for improved diabetes management and early intervention. Their technology promises quantitative, rapid results for point-of-care and at-home testing. The G1A test and several other assays are in development or early clinical/market stages, with proprietary technology cited for accuracy and ease of use[4][8][11].

Therapeutic areas: NephrologyImmunologyEndocrinologyRare Diseases
Modalities: DeviceImmunoassayAptamerBiosensorChromatographic Immunoassay
Industry: Protein Biomarker Diagnostics

Partnerships

Qualifying Therapeutic Discovery Project (investor/partner)

Beyond the preview

Go deeper on Epinex Diagnostics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Epinex Diagnostics.

Explore the full profile